MGMT and glioblastoma: The methylation status of MGMT(O-6-Methylguanine-DNA-Methyltransferase) promoter was the first biomarker to beused for patient stratification in clinical trials as a predictor of GBM response totreatment with alkylating agents (Hegi etal., 2005, 2008).